REG - Hutchmed China Ltd - Total Voting Rights

HUTCHMED (China)Announcement

28/04/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230428:nRSb7258Xa&default-theme=true

RNS Number : 7258X  Hutchmed (China) Limited  28 April 2023

 

 

Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ — Friday, April 28, 2023:
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) hereby
notifies the market that as at April 28, 2023, the issued share capital of
HUTCHMED consisted of 866,131,390 ordinary shares of US$0.10 each, with each
share carrying one right to vote and with no shares held in treasury.

 

The above figure of 866,131,390 may be used by shareholders as the denominator
for the calculations by which they could determine if they are required to
notify their interest in, or a change to their interest in, HUTCHMED under the
Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For illustrative purposes only, the 866,131,390 ordinary shares would be
equivalent to 866,131,390 depositary interests (each equating to one ordinary
share) which are traded on AIM or, if the depositary interests were converted
in their entirety, equivalent to 173,226,278 American depositary shares (each
equating to five ordinary shares) which are traded on Nasdaq.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 5,000
personnel across all its companies, at the center of which is a team of about
1,800 in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three oncology drugs now approved and marketed in China.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Contacts

 Investor Enquiries
 Mark Lee, Senior Vice President                    +852 2121 8200
 Annie Cheng, Vice President                        +1 (973) 306-4490

 Media Enquiries
 Americas – Brad Miles,                             +1 (917) 570 7340 (Mobile) / bmiles@soleburystrat.com

                                                  (mailto:bmiles@soleburystrat.com)
 Solebury Strategic Communications
 Europe –  Ben Atwell / Alex Shaw,                  +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

                                                  +44 7779 545 055 (Mobile)
 FTI Consulting                                     HUTCHMED@fticonsulting.com (mailto:hutchmed@fticonsulting.com)
 Asia –  Zhou Yi, Brunswick                         +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                    (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley, Panmure Gordon   +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRZZGZDGNDGFZM